Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

NCT ID: NCT07039461

Last Updated: 2026-01-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-12
• Study Completion Date: 2025-12-24

Brief Summary

To study the effectiveness and safety of IPL treatment for Chalazion

Detailed Description

The study aims to evaluate the effectiveness and safety of IPL therapy for the treatment of chalazion. The effect of IPL on chalazion will be examined in a masked randomized controlled study. Subjects in the study arm will be treated with IPL, while subjects in the control arm will be treated with sham IPL. A significant difference in the outcomes of the two arms will provide support for a genuine contribution of the IPL treatment

Conditions

Chalazion

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Study arm

subjects in the study arm will receive active IPL treatment

Group Type: EXPERIMENTAL

OptiLIGHT

Intervention Type: DEVICE

three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment

Control arm

subjects in the control arm will receive sham IPL treatment

Group Type: SHAM_COMPARATOR

OptiLIGHT

Intervention Type: DEVICE

three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment

Interventions

OptiLIGHT

three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject is able to read, understand, and sign an Informed Consent Form (ICF)
• 18 years of age or older
• Clinical diagnosis of acute chalazion, present for a maximum of 4 weeks
• Subject is willing to comply with all study procedures

Exclusion Criteria

• Subjects who underwent IPL treatment less than 6 months prior to screening
• Concurrent eyelid infection, which to the opinion of the study investigator is not related to the chalazion
• Chalazion with atypical features, which to the opinion of the study investigator is inadequate for a study
• Chronic Chalazion
• Recurring Chalazion
• Floppy eyelid syndrome
• Demodex blepharitis patients taking Lotilaner ophthalmic solution within 30 days prior to screening
• Ocular surgery within 3 months prior to screening
• Current diagnosis of malignant tumors in the affected eyelid, including: sebaceous carcinoma and basal cell carcinoma
• Laser Assisted In Situ Keratomileusis (LASIK)/Small Incision Lenticule Extraction (SMILE) surgery, within 1 year prior to screening
• Radial Keratotomy (RK) surgery
• Recent ocular trauma, within 3 months prior to screening
• Pre-cancerous lesions or skin cancer in the planned treatment area
• Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
• Uncontrolled infections or uncontrolled immunosuppressive diseases
• Best corrected visual acuity worse than 20/200 in either eye
• Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., prior chemical burn, Epithelial Basement Membrane Dystrophy - EBMD)
• Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
• Active sun burn in the treatment area
• Anterior chamber inflammation
• Corneal edema
• Any condition revealed whereby the investigator deems the subject inappropriate for this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Lumenis Be Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

James Chelnis, MD

Role: PRINCIPAL_INVESTIGATOR

Manhattan Face and Eye

Laura Periman, MD

Role: PRINCIPAL_INVESTIGATOR

Periman Eye Institute

Locations

Manhattan Face and Eye clinic

New York, New York, United States

Periman Eye Institute

Seattle, Washington, United States

Countries

United States

Other Identifiers

LUM-VBU-OPT-25-01

Identifier Type: -

Identifier Source: org_study_id